Article
Immunology
Rong Wang, Man Chen, Minjing Fu, Wei Zhao, Jing Zhou, Meiwei Gong, Qingqing Wu, Hui Wang
Summary: This study discusses the effects of mobilizing healthy donors with G-CSF on the absolute values and functions of MDSCs and their subpopulations in peripheral blood, as well as the impacts of transferring MDSCs from the graft to patients on their prognosis and immune reconstitution. The results show that G-CSF significantly increases the levels of MDSCs in the peripheral blood of donors, and the level of transferred P-MDSCs has a significant impact on the prognosis of patients. Maintaining a balanced state of MDSCs is crucial for effective immunotherapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Hong-Wei Sun, Wen-Chao Wu, Hai-Tian Chen, Yi-Tuo Xu, Yan-Yan Yang, Jing Chen, Xing-Juan Yu, Zilian Wang, Ze-Yu Shuang, Limin Zheng
Summary: The study demonstrates that glutamine deprivation can enhance the expression of G-CSF and GM-CSF in breast cancer cells, leading to generation of immunosuppressive myeloid-derived suppressor cells (MDSCs) due to impaired HPC-maintaining capacity in the bone marrow.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Vibhuti Aggarwal, Waleed Sabry, Mohamed Elemary, Mark Bosch, Pat Danyluk, Prosanta Mondal, Julie Stakiw
Summary: The study aimed to validate the clinical comparability of biosimilar G-CSF to its reference product in a real-world clinical setting, showing no clinically meaningful differences were detected between originator Neupogen and biosimilar Grastofil in terms of stem cell collection and engraftment post ASCT. Biosimilars are safe and effective as originator products, supporting their implementation across all approved indications for cost savings and optimal allocation of healthcare resources.
Article
Biochemistry & Molecular Biology
Zachary D. Crees, Michael P. Rettig, Reyka G. Jayasinghe, Keith Stockerl-Goldstein, Sarah M. Larson, Illes Arpad, Giulio A. Milone, Massimo Martino, Patrick Stiff, Douglas Sborov, Denise Pereira, Ivana Micallef, Gemma Moreno-Jimenez, Gabor Mikala, Maria Liz Paciello Coronel, Udo Holtick, John Hiemenz, Muzaffar H. Qazilbash, Nancy Hardy, Tahir Latif, Irene Garcia-Cadenas, Abi Vainstein-Haras, Ella Sorani, Irit Gliko-Kabir, Inbal Goldstein, Debby Ickowicz, Liron Shemesh-Darvish, Shaul Kadosh, Feng Gao, Mark A. Schroeder, Ravi Vij, John F. DiPersio
Summary: Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). Motixafortide combined with G-CSF significantly improves the collection of CD34(+) hematopoietic stem cells compared to G-CSF alone. Motixafortide + G-CSF demonstrates superior efficacy in ASCT.
Article
Biochemistry & Molecular Biology
Attya Omer-Javed, Gabriele Pedrazzani, Luisa Albano, Sherash Ghaus, Claire Latroche, Maura Manzi, Samuele Ferrari, Martina Fiumara, Aurelien Jacob, Valentina Vavassori, Alessandro Nonis, Daniele Canarutto, Luigi Naldini
Summary: Hematopoietic stem/progenitor cell gene therapy has been successful in treating genetic diseases. Mobilizers provide an opportunity for exogenous cells to efficiently replace depleted bone marrow through competition. This competitive advantage is achieved by rescuing the detrimental effects of mobilization on hematopoietic stem/progenitor cells during ex vivo culture, and can be further enhanced by transient overexpression of engraftment effectors.
Article
Rheumatology
Ann-Christin Pecher, Katharina Renate Ach, Wichard Vogel, Joerg Christoph Henes
Summary: This study evaluated the feasibility of reducing cyclophosphamide dosing in mobilization chemotherapy for SSc patients undergoing autologous stem cell transplantation. The results showed that reducing cyclophosphamide dosing did not affect stem cell collection, and higher doses of cyclophosphamide may be associated with more side effects. Risk factors for poor mobilization included low body weight, prior rituximab therapy, and cardiac involvement.
Article
Gastroenterology & Hepatology
Cornelius Engelmann, Adam Herber, Annegret Franke, Tony Bruns, Philipp Reuken, Ingolf Schiefke, Alexander Zipprich, Stefan Zeuzem, Tobias Goeser, Ali Canbay, Christoph Berg, Jonel Trebicka, Frank E. Uschner, Johannes Chang, Tobias Mueller, Niklas Aehling, Moritz Schmelzle, Katrin Splith, Frank Lammert, Christian M. Lange, Christoph Sarrazin, Christian Trautwein, Michael Manns, Dieter Haeussinger, Jan Pfeiffenberger, Peter R. Galle, Anett Schmiedeknecht, Thomas Berg
Summary: In this multicenter controlled trial, G-CSF did not show significant beneficial effects on ACLF patients compared to standard medical therapy alone. The study was terminated prematurely due to futility after analysis. Therefore, G-CSF should not be recommended as a standard treatment for ACLF.
JOURNAL OF HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Flavy Roseren, Martine Pithioux, Stephane Robert, Laure Balasse, Benjamin Guillet, Edouard Lamy, Sandrine Roffino
Summary: The study showed that G-CSF can accelerate bone regeneration and modulate the mobilization of progenitor cells during the process of distraction osteogenesis, promoting bone consolidation. In the early phase of consolidation, the G-CSF group exhibited lower osteoclast activity and a trend of increased osteoblast activity, while significantly lower neovascularization was observed in the late phase of consolidation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell & Tissue Engineering
Naokazu Nakamura, Tomoyasu Jo, Yasuyuki Arai, Mayumi Matsumoto, Tomomi Sakai, Hiroko Tsunemine, Akifumi Takaori-Kondo, Nobuyoshi Arima
Summary: In a retrospective cohort study of 43 Japanese patients undergoing autologous stem cell transplantation, it was found that the use of plerixafor resulted in a shorter time to neutrophil and platelet engraftment compared to not using plerixafor. Additionally, the incidence of sepsis was significantly lower in the plerixafor group.
Article
Hematology
Grace Gifford, Luke Hesson, Jason W. H. Wong, Adam Carroll, Sara Gabrielli, LiJun Bai, Wei Xia, William Stevenson, Matthew Greenwood
Summary: Clonal hematopoiesis of indeterminant potential (CHIP) increases with age and may affect the mobilization of autologous CD34+ peripheral blood stem cells. This study shows that somatic mutations in certain genes can predict poor mobilization of CD34+ PBSC, potentially reducing mobilization and graft failures.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Oncology
Selina Buehler, Dilara Akhoundova, Barbara Jeker, Myriam Legros, Katja Seipel, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
Summary: High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for multiple myeloma (MM). This study evaluated the safety and efficacy of using ixazomib in combination with G-CSF for stem cell mobilization in MM patients. The combination showed promising mobilizing activity, although some patients required the addition of plerixafor for optimal stem cell collection.
Article
Oncology
Kimo Bachiashvili, Liton Francisco, Yanjun Chen, Alysia Bosworth, Stephen J. Forman, Ravi Bhatia, Smita Bhatia
Summary: Therapy-related myeloid neoplasms (t-MN) are a major cause of nonrelapse mortality after autologous peripheral blood stem cell transplantation (aPBSCT) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphomas (NHL). This study found that abnormalities in peripheral blood parameters (such as hemoglobin, hematocrit, white blood cell, and platelet counts) can help identify patients at high risk for t-MN, allowing for personalized close surveillance and potential interventions.
Article
Oncology
Eun Hee Jung, Ja Min Byun, Dong-Yeop Shin, Young Rok Do, Jae-Cheol Jo, Sang Min Lee, Sung-Soo Yoon
Summary: The use of Lenograstim, a glycosylated recombinant form of G-CSF, effectively mobilizes hematopoietic progenitor cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant. The majority of patients achieved the target CD34+ cell collection with subcutaneous administration of Lenograstim. The study demonstrates the safety and efficacy of Lenograstim in MM autologous settings.
Article
Hematology
Anelise Bergmann Araujo, Tahiane Brum Soares, Tissiana Schmalfuss, Melissa Helena Angeli, Juliana Monteiro Furlan, Gabrielle Dias Salton, Mariana Monteiro Burin, Liane Marise Rohsig
Summary: This study compared the transplant-related outcomes of two graft preservation methods: fresh storage and cryopreservation. The results showed that the infusion of fresh peripheral blood stem cells (PBSC) refrigerated for up to three days had faster neutrophil engraftment and fewer adverse effects compared to cryopreserved PBSC transplantation.
Article
Oncology
Paul Cornes, John Kelton, Rongzhe Liu, Omer Zaidi, Jennifer Stephens, Jingyan Yang
Summary: This study evaluated the cost-effectiveness of pegfilgrastim versus filgrastim in cancer patients at intermediate-to-high risk of chemotherapy-induced febrile neutropenia (FN) using real-world data. The results showed that pegfilgrastim biosimilars have the potential to optimize FN management economically and improve health outcomes.
